ROIV Roivant Sciences Ltd.
Healthcare$29.61+0.00%OpenMarket Cap: $21.30B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
4.65
P/S
2608.88
EV/EBITDA
-15.78
DCF Value
$2.88
FCF Yield
-3.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
84.4%
Operating Margin
-15560.6%
Net Margin
-3629.2%
ROE
-6.9%
ROA
-5.2%
ROIC
-23.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 null | $2.5M | 87.3% | $-355.0M | $303.0M | $— | — |
| FY null | $8.3M | 84.4% | $-1.29B | $-299.8M | $— | — |
| Q3 null | $2.0M | 65.0% | $-339.2M | $-265.9M | $— | — |
| Q2 null | $1.6M | 92.9% | $-306.2M | $-113.5M | $— | — |
| Q1 null | $2.2M | 92.9% | $-284.9M | $-223.4M | $— | — |
| Q4 null | $7.6M | 97.3% | $-285.0M | $-206.5M | $— | — |
| FY null | $29.1M | 96.9% | $-1.11B | $-172.0M | $— | — |
| Q3 null | $9.0M | 97.1% | $-274.4M | $169.4M | $— | — |
| Q2 null | $4.5M | 94.8% | $-341.7M | $-230.2M | $— | — |
| Q2 null | $4.5M | 94.8% | $-341.7M | $-230.2M | $— | — |
| Q1 null | $8.0M | 97.3% | $-102.2M | $95.3M | $— | — |
| Q4 null | $9.0M | 75.1% | $-206.8M | $-151.1M | $— | — |